Table II.
Associations between expression of RFX1 mRNA and clinicopathological parameters in 167 patients with breast cancer.
| Clinicopathological parameter | The low RFX1 group (n=124) | The high RFX1 group (n=43) | P-value |
|---|---|---|---|
| Age | |||
| ≤60 year | 78 | 30 | |
| >60 year | 46 | 13 | 0.413 |
| Histology | |||
| DCIS | 4 | 3 | |
| IDC | 110 | 38 | |
| ILC | 5 | 2 | |
| Others | 5 | 0 | 0.265 |
| UICC T factor | |||
| Tis/T1 | 51 | 26 | |
| T2/T3/T4 | 73 | 17 | 0.028a |
| Node status | |||
| Negative | 62 | 23 | |
| Positive | 62 | 20 | 0.693 |
| UICC pathological stage | |||
| 0/I/II | 92 | 39 | |
| III/IV | 32 | 4 | 0.015a |
| ER status | |||
| Positive | 88 | 39 | |
| Negative | 36 | 4 | 0.005a |
| PgR status | |||
| Positive | 79 | 36 | |
| Negative | 45 | 7 | 0.011a |
| HER2 status | |||
| Positive | 37 | 2 | |
| Negative | 82 | 37 | |
| Unknown | 5 | 4 | 0.001a |
| Triple-negative | |||
| True | 15 | 3 | |
| False | 108 | 40 | |
| Unknown | 1 | 0 | 0.323 |
| Adjuvant therapy | |||
| Endocrine therapy alone | 35 | 22 | |
| Chemotherapy alone | 27 | 3 | |
| Endocrine and chemotherapy | 48 | 16 | |
| None | 14 | 2 | 0.012a |
χ2 test.
a
Statistically significant (P<0.05). DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; UICC, union for international cancer control; Tis, carcinoma in situ; ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor 2.